A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...

The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.

Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...

RAs, originally for diabetes, may impact brain health, finding potential benefits for dementia and addiction but inconsistent ...

Share on Pinterest GLP-1 and SGLT-2 drugs may be the best treatments ... people globally living with chronic obstructive pulmonary disease (COPD) will hit 600 million by 2050.

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative. The stock is reasonably valued given the growth opportunities in front ...

Clinical studies have revealed that rasagiline is associated with improved outcomes in patients with early Parkinson's disease (PD ... therapeutic dosage is 0.5-1 mg administered orally once ...

Most adults who have taken GLP-1 drugs say they took them to treat a chronic condition including diabetes or heart disease (62%), while about four in ten say they took them primarily to lose ...

When Trova Wine and Market shut its doors last month after nearly five years in Dallas, owner Michelle Bonds pointed to an unexpected reason for closure: GLP-1 weight loss drugs like Ozempic.